The Future of Joint Replacement — What Is Coming

Part of The Joint Replacement Guide — Phase 6: The Bigger Picture · Article 44 of 44 · Hip & Knee

Key Points

  • Conventional hip and knee replacement already has a strong evidence base and will remain the benchmark against which newer technologies are assessed.
  • Robotic and computer-assisted systems can improve the precision of implant positioning, but better long-term patient outcomes have not yet been established.
  • Improvements in implants, anaesthesia, infection prevention and recovery are likely to remain gradual rather than revolutionary.
  • Same-day or next-day discharge will become appropriate for more patients, but discharge should be based on safety and readiness—not a target applied to everyone.
  • Registries such as the National Joint Registry will remain central to identifying both successful developments and unexpected problems.

A Strong Starting Point

It is easy for discussion about the “future” to imply that current joint replacement is becoming outdated. That would be misleading.

Conventional hip and knee replacement, performed by an experienced team using established implants and careful technique, already provides reliable pain relief and improved function for most appropriately selected patients. New technology must demonstrate that it adds worthwhile patient benefit, safety or value when compared with this established standard.

A newer or more expensive technique is not automatically a better one.

Robotic and Computer-Assisted Surgery

Robotic and computer-assisted systems are likely to be used in more hospitals as research and service evaluation continue. These systems help the surgeon plan bone preparation and implant positioning; they do not replace the surgeon or operate independently.

The clearest established advantage is greater precision and fewer alignment outliers. However, NICE concluded in 2025 that patient-reported outcomes, complications and revision outcomes were broadly similar to conventional surgery in the available evidence. More precise alignment had not yet been shown to produce better clinical outcomes.[1]

NICE has allowed six robotic systems to be used in the NHS during a three-year evidence-generation period, subject to regulatory and data-collection requirements. Important uncertainties remain around:

  • quality of life and patient-reported outcomes;
  • revision rates and implant survival;
  • theatre time, staffing and training;
  • additional imaging and consumables;
  • cost-effectiveness; and
  • which patients, if any, benefit most.[1,2]

Robotic assistance should therefore be presented as a developing surgical tool—not as a guarantee of better recovery, less pain or a longer-lasting implant. Lack of access to a robot does not indicate a lower standard of care.

Safe introduction also requires training of the whole theatre team, monitoring of the learning curve and clear local governance. The British Orthopaedic Association has published guidance to support hospitals introducing these services.[3]

More Individualised Planning

Computer navigation, robotic systems and improved imaging make it easier to plan implant position around an individual patient’s anatomy. In knee replacement, this has contributed to continuing research into mechanical, kinematic and other personalised alignment strategies.

Greater technical ability to reproduce a chosen plan does not establish which plan is best for every patient. Alignment remains an evolving and debated area, and long-term outcomes are still required before one philosophy can be described as universally superior.

Patient-specific instruments and custom-made implants may be helpful in selected unusual or complex cases. For routine primary replacement, they should not be assumed to improve outcomes simply because they are described as personalised.

Implant Materials and Design

Implant development is likely to focus on incremental improvements in:

  • wear resistance;
  • fixation to bone;
  • stability and range of component sizes;
  • designs intended to reduce dislocation or instability;
  • preservation of bone for any future revision; and
  • compatibility with different surgical and alignment strategies.

New implants also bring uncertainty. Their true durability may not become apparent until they have been used in many patients and followed for several years.

The National Joint Registry analyses implant performance and investigates potential outliers, working with bodies including the Medicines and Healthcare products Regulatory Agency. Its Implant Scrutiny Committee reviews data regularly and can notify the regulator when concerns arise.[4]

Programmes such as Beyond Compliance support the controlled, stepwise introduction and monitoring of new or modified implants before they are adopted widely.[5] This is important because innovation should occur alongside surveillance, not ahead of it.

Infection Prevention

Research continues into antimicrobial implant coatings, improved wound dressings, more targeted antibiotics, rapid testing for infection and methods of identifying patients at increased risk.

Some of these developments are promising, particularly for revision surgery or patients at unusually high risk. Many remain investigational or suitable only for selected circumstances. No coating or new technology removes the need for established infection-prevention measures such as appropriate antibiotics, skin preparation, sterile technique and optimisation of modifiable risks.

Recovery and Shorter Hospital Stays

Enhanced recovery pathways will continue to develop through improved patient preparation, anaesthesia, pain relief, early mobilisation and coordinated discharge planning.

GIRFT guidance supports a zero- or one-night pathway for many suitable primary hip and knee replacement patients, while recognising that people with additional medical or care needs may require longer admission.[6]

Same-day discharge is not the definition of a successful operation. A patient should leave hospital only when they:

  • are medically stable;
  • have manageable pain and nausea;
  • can mobilise safely;
  • can manage any necessary stairs;
  • understand their medication and wound care;
  • have appropriate support and transport; and
  • know whom to contact if a problem develops.

For some people, going home on the day of surgery is appropriate and welcome. For others, one or more nights in hospital is safer. Future pathways should become more individualised, not simply shorter.

Digital Rehabilitation and Follow-Up

Digital platforms, wearable activity monitors, video consultations and remotely submitted questionnaires may increasingly support rehabilitation and follow-up. Potential benefits include easier access to advice, earlier identification of patients whose recovery is falling behind and more convenient monitoring for people who live far from the hospital.

Digital care should supplement—not automatically replace—clinical assessment. Not every patient has reliable internet access, confidence with technology or a home environment suitable for remote rehabilitation. Services will need non-digital alternatives to avoid widening inequality.

NICE is currently evaluating digital platforms used before and after elective hip and knee replacement, reflecting both their potential and the need for evidence before widespread adoption.[7]

Registry Data, Prediction and Artificial Intelligence

The NJR already allows implants, hospitals and surgical outcomes to be monitored at a scale that individual trials cannot easily achieve. Future developments may include linking registry data more effectively with patient-reported outcomes, prescribing records, imaging and other healthcare information.

Statistical models and artificial intelligence may help estimate an individual patient’s risks or likely improvement. These tools could support shared decision-making, but they cannot replace clinical judgement. Their accuracy depends on the quality and representativeness of the data used to develop them, and they must be tested for bias, privacy, transparency and performance in real clinical practice.

A risk estimate should inform a conversation—not make the decision for the patient or surgeon.

Biological Treatments and Cartilage Repair

Research into cartilage repair, tissue engineering, cell-based treatments and biological therapies may improve treatment for certain localised cartilage injuries or earlier-stage disease.

These approaches are not currently established alternatives to hip or knee replacement for advanced, widespread osteoarthritis. Claims that an injection or unproven regenerative treatment can reliably regrow an extensively worn joint should be treated cautiously.

Future biological treatments may eventually delay joint replacement for some carefully selected patients, but this should not be promised and should not lead someone with severe disease to postpone effective treatment without sound clinical advice.

A Realistic View of Progress

The most valuable future improvements may be less visible than a robot or a new implant. They may include:

  • better identification and treatment of anaemia and diabetes;
  • improved infection and blood-clot prevention;
  • safer pain relief with less reliance on opioids;
  • better selection and preparation of patients;
  • stronger rehabilitation and follow-up;
  • earlier recognition of failing implants; and
  • more consistent delivery of proven care.

These changes are usually incremental, but their combined effect across thousands of patients can be substantial.

New technologies should progress through careful evaluation, appropriate regulation, professional training and continued registry surveillance. Some will become established; others may prove to add little or may be withdrawn. This cautious process protects patients while allowing worthwhile innovation to develop.

What This Means for You

You do not need to delay an appropriate joint replacement simply because a newer robot, implant or biological treatment may become available in the future.

When considering a new technology, useful questions include:

  • What specific problem is this intended to solve in my case?
  • What evidence shows that it improves outcomes that matter to patients?
  • Are the benefits established or still theoretical?
  • What additional risks, imaging or costs are involved?
  • How experienced is the surgeon and team with it?
  • Is its use being recorded in the National Joint Registry or another surveillance programme?
  • Would a conventional operation be expected to produce a similarly good result?

The aim should not be to obtain the newest treatment. It should be to receive the most appropriate, evidence-supported treatment for your individual circumstances.

This article provides general information and does not replace individual clinical advice. Technologies and guidance continue to change; your surgeon should explain whether any newer option offers a meaningful advantage in your particular case.

References

  1. National Institute for Health and Care Excellence. Robot-assisted surgery for orthopaedic procedures: recommendations. HealthTech guidance HTG743; 2025.
  2. National Institute for Health and Care Excellence. Evidence-generation plan for robot-assisted orthopaedic surgery. 2025.
  3. British Orthopaedic Association. Robotics in orthopaedics.
  4. National Joint Registry. Implant Scrutiny Committee.
  5. National Joint Registry. Beyond Compliance and the stepwise introduction of new implants.
  6. Getting It Right First Time. Guidance for ambulatory hip and knee replacement surgery.
  7. National Institute for Health and Care Excellence. Digital platforms supporting rehabilitation before and after primary hip or knee replacement.

← Back to the Joint Replacement Guide · Previous: The Psychology of Chronic Pain and Surgical Outcomes

This is the final article in The Joint Replacement Guide. Thank you for reading — you can revisit any section at any time from the main guide page.